SEC Form 4 · accession 0001140361-15-016863
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Hoey
Officer — SVP, Cancer Biology
Period of report
Apr 27, 2015
Accepted (ET)
Apr 29, 2015 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 27, 2015 | M | 5,000 | $1.43 | A | 56,230 | D | |
| Common StockF3,F2 | Apr 27, 2015 | S | 3,537 | $25.124 | D | 52,693 | D | |
| Common StockF4,F2 | Apr 27, 2015 | S | 3,350 | $26.2034 | D | 49,343 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $1.43 | Apr 27, 2015 | M | 5,000 | D | — | Jan 10, 2017 | Common Stock | 5,000 | 30,263 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 26, 2015.
- F2Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Also includes 1,285 shares acquired under the Issuer's Employee Stock Purchase Plan on February 27, 2015.
- F3This transaction was executed in multiple trades in prices ranging from $24.86 to $25.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4This transaction was executed in multiple trades in prices ranging from $25.995 to $26.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.